Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cullinan Therapeutics, Inc. (CGEM) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Cullinan Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1789972.
Total stock buying since 2021: $38,295,606.
Total stock sales since 2021: $32,917,492.
Total stock option exercises since 2021: $1,946,324.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 4,000 | $50,040 | 0 | $0 |
| 2024 | 0 | $0 | 223,902 | $4,095,717 | 189,931 | $977,216 |
| 2023 | 0 | $0 | 36,608 | $379,319 | 12,000 | $51,600 |
| 2022 | 2,145,386 | $21,395,856 | 646,551 | $7,141,708 | 156,374 | $672,408 |
| 2021 | 804,750 | $16,899,750 | 737,490 | $21,250,708 | 57,000 | $245,100 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-01 | 0 | $0 | 4,000 | $50,040 | 0 | $0 |
| 2024-12 | 0 | $0 | 16,296 | $189,809 | 0 | $0 |
| 2024-11 | 0 | $0 | 8,000 | $125,120 | 0 | $0 |
| 2024-09 | 0 | $0 | 8,000 | $144,720 | 0 | $0 |
| 2024-07 | 0 | $0 | 8,000 | $130,639 | 0 | $0 |
| 2024-06 | 0 | $0 | 0 | $0 | 18,450 | $239,850 |
| 2024-05 | 0 | $0 | 63,606 | $1,802,956 | 55,606 | $239,105 |
| 2024-02 | 0 | $0 | 40,000 | $647,200 | 40,000 | $172,000 |
| 2024-01 | 0 | $0 | 80,000 | $1,055,273 | 75,875 | $326,261 |
| 2023-12 | 0 | $0 | 14,903 | $127,400 | 0 | $0 |
| 2023-06 | 0 | $0 | 14,569 | $179,884 | 12,000 | $51,600 |
| 2023-05 | 0 | $0 | 2,570 | $22,797 | 0 | $0 |
| 2023-04 | 0 | $0 | 2,528 | $26,742 | 0 | $0 |
| 2023-03 | 0 | $0 | 2,038 | $22,496 | 0 | $0 |
| 2022-11 | 0 | $0 | 4,000 | $53,200 | 4,000 | $17,200 |
| 2022-09 | 0 | $0 | 4,000 | $49,600 | 4,000 | $17,200 |
| 2022-08 | 0 | $0 | 49,910 | $711,689 | 0 | $0 |
| 2022-07 | 0 | $0 | 68,000 | $963,272 | 8,000 | $34,400 |
| 2022-06 | 759,486 | $8,364,920 | 101,903 | $1,304,847 | 140,374 | $603,608 |
| 2022-05 | 1,109,900 | $10,063,936 | 418,738 | $4,059,100 | 0 | $0 |
| 2022-04 | 276,000 | $2,967,000 | 0 | $0 | 0 | $0 |
| 2021-10 | 0 | $0 | 32,653 | $805,805 | 12,000 | $51,600 |
| 2021-09 | 0 | $0 | 300,833 | $8,720,193 | 30,000 | $129,000 |
| 2021-08 | 0 | $0 | 404,004 | $11,724,710 | 15,000 | $64,500 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-06 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 4,000 | 12.51 | 50,040 |
| 2024-12-18 | Jones Jeffrey Alan (Chief Medical Officer) | Sale | 4,632 | 11.41 | 52,851 |
| 2024-12-18 | Sumer Jacquelyn L (Chief Legal Officer) | Sale | 3,482 | 11.41 | 39,729 |
| 2024-12-18 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 4,693 | 11.41 | 53,547 |
| 2024-12-12 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 3,489 | 12.52 | 43,682 |
| 2024-11-05 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 8,000 | 15.64 | 125,120 |
| 2024-09-05 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 8,000 | 18.09 | 144,720 |
| 2024-07-05 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 8,000 | 16.33 | 130,639 |
| 2024-06-10 | Ebeling Thomas | Option Ex | 18,450 | 13.00 | 239,850 |
| 2024-05-07 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 5,606 | 30.06 | 168,516 |
| 2024-05-07 | Michaelson Jennifer (Chief Scientific Officer) | Option Ex | 5,606 | 4.30 | 24,105 |
| 2024-05-06 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 58,000 | 28.18 | 1,634,440 |
| 2024-05-06 | Michaelson Jennifer (Chief Scientific Officer) | Option Ex | 50,000 | 4.30 | 215,000 |
| 2024-02-01 | Savill Corrine (Chief Business Officer) | Sale | 40,000 | 16.18 | 647,200 |
| 2024-02-01 | Savill Corrine (Chief Business Officer) | Option Ex | 40,000 | 4.30 | 172,000 |
| 2024-01-29 | Savill Corrine (Chief Business Officer) | Sale | 40,000 | 14.09 | 563,600 |
| 2024-01-29 | Savill Corrine (Chief Business Officer) | Option Ex | 40,000 | 4.30 | 172,000 |
| 2024-01-23 | Savill Corrine (Chief Business Officer) | Sale | 21,316 | 12.46 | 265,597 |
| 2024-01-23 | Savill Corrine (Chief Business Officer) | Option Ex | 21,316 | 4.30 | 91,658 |
| 2024-01-22 | Savill Corrine (Chief Business Officer) | Sale | 18,684 | 12.10 | 226,076 |
| 2024-01-22 | Savill Corrine (Chief Business Officer) | Option Ex | 14,559 | 4.30 | 62,603 |
| 2023-12-26 | Ahmed Nadim (President and CEO) | Sale | 4,272 | 9.24 | 39,473 |
| 2023-12-21 | Jones Jeffrey Alan (Chief Medical Officer) | Sale | 1,860 | 8.50 | 15,810 |
| 2023-12-21 | Sumer Jacquelyn L (Chief Legal Officer) | Sale | 1,400 | 8.50 | 11,900 |
| 2023-12-21 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 1,920 | 8.50 | 16,320 |
| 2023-12-21 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 1,145 | 8.50 | 9,732 |
| 2023-12-18 | Jones Jeffrey Alan (Chief Medical Officer) | Sale | 386 | 8.22 | 3,172 |
| 2023-12-18 | Sumer Jacquelyn L (Chief Legal Officer) | Sale | 290 | 8.22 | 2,383 |
| 2023-12-18 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 398 | 8.22 | 3,271 |
| 2023-12-18 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 238 | 8.22 | 1,956 |
| 2023-12-12 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 1,926 | 7.81 | 15,042 |
| 2023-12-12 | Michaelson Jennifer (Chief Scientific Officer) | Sale | 1,068 | 7.81 | 8,341 |
| 2023-06-28 | Ahmed Nadim (President and CEO) | Sale | 759 | 11.40 | 8,652 |
| 2023-06-20 | Jones Jeffrey Alan (Chief Medical Officer) | Sale | 387 | 12.94 | 5,007 |
| 2023-06-20 | Sumer Jacquelyn L (Chief Legal Officer) | Sale | 291 | 12.94 | 3,765 |
| 2023-06-20 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 399 | 12.94 | 5,163 |
| 2023-06-20 | Michaelson Jennifer (Chief Development Officer) | Sale | 238 | 12.94 | 3,079 |
| 2023-06-12 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 319 | 13.11 | 4,182 |
| 2023-06-12 | Michaelson Jennifer (Chief Development Officer) | Sale | 176 | 13.11 | 2,307 |
| 2023-06-07 | Michaelson Jennifer (Chief Development Officer) | Sale | 100 | 12.40 | 1,240 |
| 2023-06-07 | Michaelson Jennifer (Chief Development Officer) | Option Ex | 100 | 4.30 | 430 |
| 2023-06-06 | Michaelson Jennifer (Chief Development Officer) | Sale | 11,900 | 12.31 | 146,489 |
| 2023-06-06 | Michaelson Jennifer (Chief Development Officer) | Option Ex | 11,900 | 4.30 | 51,170 |
| 2023-05-23 | Ahmed Nadim (President and CEO) | Sale | 707 | 9.15 | 6,469 |
| 2023-05-18 | Jones Jeffrey Alan (Chief Medical Officer) | Sale | 394 | 8.76 | 3,451 |
| 2023-05-18 | Sumer Jacquelyn L (Chief Legal Officer) | Sale | 291 | 8.76 | 2,549 |
| 2023-05-18 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 399 | 8.76 | 3,495 |
| 2023-05-18 | Michaelson Jennifer (Chief Development Officer) | Sale | 239 | 8.76 | 2,093 |
| 2023-05-12 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 347 | 8.78 | 3,046 |
| 2023-05-12 | Michaelson Jennifer (Chief Development Officer) | Sale | 193 | 8.78 | 1,694 |
| 2023-04-25 | Ahmed Nadim (President and CEO) | Sale | 716 | 10.59 | 7,582 |
| 2023-04-18 | Jones Jeffrey Alan (Chief Medical Officer) | Sale | 392 | 10.71 | 4,198 |
| 2023-04-18 | Sumer Jacquelyn L (Chief Legal Officer) | Sale | 290 | 10.71 | 3,105 |
| 2023-04-18 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 398 | 10.71 | 4,262 |
| 2023-04-18 | Michaelson Jennifer (Chief Development Officer) | Sale | 238 | 10.71 | 2,548 |
| 2023-04-12 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 318 | 10.22 | 3,249 |
| 2023-04-12 | Michaelson Jennifer (Chief Development Officer) | Sale | 176 | 10.22 | 1,798 |
| 2023-03-23 | Ahmed Nadim (President and CEO) | Sale | 706 | 10.51 | 7,420 |
| 2023-03-20 | Jones Jeffrey Alan (Chief Medical Officer) | Sale | 390 | 11.32 | 4,414 |
| 2023-03-20 | Sumer Jacquelyn L (Chief Legal Officer) | Sale | 305 | 11.32 | 3,452 |
| 2023-03-20 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 399 | 11.32 | 4,516 |
| 2023-03-20 | Michaelson Jennifer (Chief Development Officer) | Sale | 238 | 11.32 | 2,694 |
| 2022-11-25 | Michaelson Jennifer (See Remarks) | Sale | 4,000 | 13.30 | 53,200 |
| 2022-11-25 | Michaelson Jennifer (See Remarks) | Option Ex | 4,000 | 4.30 | 17,200 |
| 2022-09-27 | Michaelson Jennifer (See Remarks) | Sale | 4,000 | 12.40 | 49,600 |
| 2022-09-27 | Michaelson Jennifer (See Remarks) | Option Ex | 4,000 | 4.30 | 17,200 |
| 2022-08-04 | Jovan-embiricos Morana | Sale | 25,989 | 14.31 | 371,798 |
| 2022-08-03 | Jovan-embiricos Morana | Sale | 19,129 | 14.24 | 272,339 |
| 2022-08-02 | Jovan-embiricos Morana | Sale | 4,792 | 14.10 | 67,552 |
| 2022-07-25 | Michaelson Jennifer (Chief Development Officer) | Sale | 8,000 | 14.51 | 116,080 |
| 2022-07-25 | Michaelson Jennifer (Chief Development Officer) | Option Ex | 8,000 | 4.30 | 34,400 |
| 2022-07-19 | Savill Corrine (Acting Chief Business Officer) | Sale | 14,958 | 15.22 | 227,660 |
| 2022-07-18 | Savill Corrine (Acting Chief Business Officer) | Sale | 5,042 | 15.06 | 75,932 |
| 2022-07-11 | Savill Corrine (Acting Chief Business Officer) | Sale | 40,000 | 13.59 | 543,600 |
| 2022-06-24 | Jovan-embiricos Morana | Option Ex | 140,374 | 4.30 | 603,608 |
| 2022-06-23 | Jovan-embiricos Morana | Sale | 29,631 | 13.00 | 385,321 |
| 2022-06-22 | Jovan-embiricos Morana | Sale | 49,953 | 12.70 | 634,602 |
| 2022-06-21 | Jovan-embiricos Morana | Sale | 22,319 | 12.77 | 284,924 |
| 2022-06-06 | Ahmed Nadim (President and CEO) | Buy | 8,090 | 12.40 | 100,316 |
| 2022-06-01 | Lampert Mark N | Buy | 751,396 | 11.00 | 8,264,604 |
| 2022-05-16 | Jovan-embiricos Morana | Sale | 35,158 | 11.23 | 394,824 |
| 2022-05-13 | Jovan-embiricos Morana | Sale | 119,508 | 10.22 | 1,221,610 |
| 2022-05-13 | Lampert Mark N | Buy | 109,900 | 9.13 | 1,003,936 |
| 2022-05-12 | Jovan-embiricos Morana | Sale | 264,072 | 9.25 | 2,442,666 |
| 2022-05-12 | Lampert Mark N | Buy | 1,000,000 | 9.06 | 9,060,000 |
| 2022-04-01 | Lampert Mark N | Buy | 276,000 | 10.75 | 2,967,000 |
| 2021-10-18 | Michaelson Jennifer (See Remarks) | Sale | 4,000 | 22.37 | 89,480 |
| 2021-10-18 | Michaelson Jennifer (See Remarks) | Option Ex | 4,000 | 4.30 | 17,200 |
| 2021-10-15 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 8,000 | 25.00 | 200,000 |
| 2021-10-15 | Trigilio Jeffrey (Chief Financial Officer) | Option Ex | 8,000 | 4.30 | 34,400 |
| 2021-10-15 | Zawel Leigh (See Remarks) | Sale | 19,574 | 25.00 | 489,350 |
| 2021-10-07 | Zawel Leigh (See Remarks) | Sale | 1,079 | 25.00 | 26,975 |
| 2021-09-20 | Michaelson Jennifer (See Remarks) | Sale | 4,000 | 24.77 | 99,080 |
| 2021-09-20 | Michaelson Jennifer (See Remarks) | Option Ex | 4,000 | 4.30 | 17,200 |
| 2021-09-20 | Zawel Leigh (See Remarks) | Sale | 7,468 | 25.16 | 187,894 |
| 2021-09-16 | Bioimpact Capital Llc (10% Owner) | Sale | 3,124 | 29.06 | 90,783 |
| 2021-09-16 | Gadicke Ansbert (Director) | Sale | 3,556 | 29.06 | 103,337 |
| 2021-09-15 | Bioimpact Capital Llc (10% Owner) | Sale | 6,425 | 29.16 | 187,353 |
| 2021-09-15 | Gadicke Ansbert (Director) | Sale | 7,313 | 29.16 | 213,247 |
| 2021-09-14 | Bioimpact Capital Llc (10% Owner) | Sale | 7,106 | 29.17 | 207,282 |
| 2021-09-14 | Gadicke Ansbert (Director) | Sale | 8,088 | 29.17 | 235,926 |
| 2021-09-13 | Bioimpact Capital Llc (10% Owner) | Sale | 3,595 | 29.10 | 104,614 |
| 2021-09-13 | Gadicke Ansbert (Director) | Sale | 4,092 | 29.10 | 119,077 |
| 2021-09-10 | Bioimpact Capital Llc (10% Owner) | Sale | 5,931 | 29.04 | 172,236 |
| 2021-09-10 | Gadicke Ansbert (Director) | Sale | 6,751 | 29.04 | 196,049 |
| 2021-09-09 | Bioimpact Capital Llc (10% Owner) | Sale | 13,727 | 29.35 | 402,887 |
| 2021-09-09 | Gadicke Ansbert (Director) | Sale | 15,625 | 29.35 | 458,593 |
| 2021-09-08 | Trigilio Jeffrey (Chief Financial Officer) | Sale | 15,000 | 28.34 | 425,100 |
| 2021-09-08 | Trigilio Jeffrey (Chief Financial Officer) | Option Ex | 15,000 | 4.30 | 64,500 |
| 2021-09-08 | Bioimpact Capital Llc (10% Owner) | Sale | 10,842 | 29.11 | 315,610 |
| 2021-09-08 | Baeuerle Patrick (See Remarks) | Sale | 11,000 | 28.45 | 312,950 |
| 2021-09-08 | Baeuerle Patrick (See Remarks) | Option Ex | 11,000 | 4.30 | 47,300 |
| 2021-09-08 | Gadicke Ansbert (Director) | Sale | 12,341 | 29.11 | 359,246 |
| 2021-09-07 | Zawel Leigh (See Remarks) | Sale | 28,118 | 28.95 | 814,016 |
| 2021-09-07 | Bioimpact Capital Llc (10% Owner) | Sale | 25,067 | 29.04 | 727,945 |
| 2021-09-07 | Gadicke Ansbert (Director) | Sale | 28,532 | 29.04 | 828,569 |
| 2021-09-03 | Bioimpact Capital Llc (10% Owner) | Sale | 12,731 | 29.60 | 376,837 |
| 2021-09-03 | Gadicke Ansbert (Director) | Sale | 14,491 | 29.60 | 428,933 |
| 2021-09-02 | Bioimpact Capital Llc (10% Owner) | Sale | 15,757 | 29.46 | 464,201 |
| 2021-09-02 | Gadicke Ansbert (Director) | Sale | 17,935 | 29.46 | 528,365 |
| 2021-09-01 | Bioimpact Capital Llc (10% Owner) | Sale | 5,714 | 29.47 | 168,391 |
| 2021-09-01 | Gadicke Ansbert (Director) | Sale | 6,504 | 29.47 | 191,672 |
| 2021-08-31 | Bioimpact Capital Llc (10% Owner) | Sale | 2,838 | 29.79 | 84,529 |
| 2021-08-31 | Gadicke Ansbert (Director) | Sale | 3,230 | 29.79 | 96,205 |
| 2021-08-30 | Bioimpact Capital Llc (10% Owner) | Sale | 31,001 | 29.30 | 908,329 |
| 2021-08-30 | Gadicke Ansbert (Director) | Sale | 35,286 | 29.30 | 1,033,879 |
| 2021-08-27 | Bioimpact Capital Llc (10% Owner) | Sale | 13,357 | 29.09 | 388,555 |
| 2021-08-27 | Gadicke Ansbert (Director) | Sale | 15,203 | 29.09 | 442,255 |
| 2021-08-25 | Mpm Oncology Impact Management Lp (10% Owner) | Sale | 1,713 | 29.09 | 49,831 |
| 2021-08-25 | Gadicke Ansbert (Director) | Sale | 1,950 | 29.09 | 56,725 |
| 2021-08-24 | Mpm Oncology Impact Management Lp (10% Owner) | Sale | 50,822 | 29.48 | 1,498,232 |
| 2021-08-24 | Gadicke Ansbert (Director) | Sale | 57,907 | 29.48 | 1,707,098 |
| 2021-08-23 | Zawel Leigh (See Remarks) | Sale | 28,118 | 29.00 | 815,422 |
| 2021-08-23 | Mpm Oncology Impact Management Lp (10% Owner) | Sale | 53,359 | 29.11 | 1,553,280 |
| 2021-08-23 | Gadicke Ansbert (Director) | Sale | 60,735 | 29.11 | 1,767,995 |
| 2021-08-18 | Michaelson Jennifer (See Remarks) | Sale | 4,000 | 27.79 | 111,140 |
| 2021-08-18 | Michaelson Jennifer (See Remarks) | Option Ex | 4,000 | 4.30 | 17,200 |
| 2021-08-11 | Mpm Oncology Impact Management Lp (10% Owner) | Sale | 2,510 | 29.05 | 72,915 |
| 2021-08-11 | Gadicke Ansbert (Director) | Sale | 2,857 | 29.05 | 82,995 |
| 2021-08-10 | Zawel Leigh (See Remarks) | Sale | 6,914 | 27.44 | 189,740 |
| 2021-08-10 | Baeuerle Patrick (See Remarks) | Sale | 11,000 | 27.00 | 297,000 |
| 2021-08-10 | Baeuerle Patrick (See Remarks) | Option Ex | 11,000 | 4.30 | 47,300 |
| 2021-08-09 | Zawel Leigh (See Remarks) | Sale | 21,204 | 26.82 | 568,585 |
| 2021-01-12 | F2 Gc, Llc (10% Owner) | Buy | 200,000 | 21.00 | 4,200,000 |
| 2021-01-12 | Trigilio Jeffrey (Chief Financial Officer) | Buy | 2,250 | 21.00 | 47,250 |
| 2021-01-12 | Mpm Oncology Impact Management Lp (10% Owner) | Buy | 300,000 | 21.00 | 6,300,000 |
| 2021-01-12 | Hughes Owen (President and CEO) | Buy | 2,500 | 21.00 | 52,500 |
| 2021-01-12 | Gadicke Ansbert (Director) | Buy | 300,000 | 21.00 | 6,300,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of CGEM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Cullinan Therapeutics, Inc. (symbol CGEM, CIK number 1789972) see the Securities and Exchange Commission (SEC) website.